{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:40:51Z","timestamp":1791549651131,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100011404","name":"Indivior PLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Public Health"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/pubmed\/fdv150","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T02:25:45Z","timestamp":1445999145000},"page":"e368-e374","source":"Crossref","is-referenced-by-count":36,"title":["Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience"],"prefix":"10.1093","volume":"38","author":[{"given":"Nat","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"D'Agnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krajci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Littlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Alho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Somaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Icro","family":"Maremmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"key":"2016101909071924000_38.3.e368.1","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2011, 2011. https:\/\/www.unodc.org\/documents\/data-and-analysis\/WDR2011\/World_Drug_Report_2011_ebook.pdf (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.2","unstructured":"World Health Organization. Principles of Drug Dependence Treatment. Discussion paper, 2008. https:\/\/www.unodc.org\/documents\/drug-treatment\/UNODC-WHO-Principles-of-Drug-Dependence-Treatment-March08.pdf (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.3","unstructured":"Bell J . Medications in Recovery: Re-orientating Drug Dependence Treatment Appendix C\u2014Opioid Substitution Treatment and its Effectiveness: Review of the Evidence, 2012. http:\/\/www.nta.nhs.uk\/uploads\/medications-in-recovery-appendixc.pdf (7 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.05.053"},{"key":"2016101909071924000_38.3.e368.5","first-page":"295","article-title":"Prescription opioid abuse: challenges and opportunities for payers","volume":"19","author":"Katz","year":"2013","journal-title":"Am J Manage Care"},{"key":"2016101909071924000_38.3.e368.6","first-page":"25","article-title":"The extent of misuse and diversion of medication for opioid substitution treatment: a review and expert opinions","volume":"17","author":"Alho","year":"2015","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"2016101909071924000_38.3.e368.7","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-011-9296-1"},{"key":"2016101909071924000_38.3.e368.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61097-0"},{"key":"2016101909071924000_38.3.e368.9","first-page":"54","article-title":"Singapore's experience with buprenorphine (Subutex)","volume":"2","author":"Noroozi","year":"2008","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"2016101909071924000_38.3.e368.10","unstructured":"Adfam. Medications in Drug Treatment: Tackling the Risks to Children, 2014. http:\/\/www.adfam.org.uk\/cms\/docs\/adfam_ost_fullreport_web.pdf (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2011.00950.x"},{"key":"2016101909071924000_38.3.e368.12","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181ff04ca"},{"key":"2016101909071924000_38.3.e368.13","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1681"},{"key":"2016101909071924000_38.3.e368.14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.18553\/jmcp.2011.17.6.430","article-title":"Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances","volume":"17","author":"Fass","year":"2011","journal-title":"J Manage Care Pharm"},{"key":"2016101909071924000_38.3.e368.15","doi-asserted-by":"publisher","DOI":"10.1111\/add.12224"},{"key":"2016101909071924000_38.3.e368.16","doi-asserted-by":"publisher","DOI":"10.1080\/09595230500263939"},{"key":"2016101909071924000_38.3.e368.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.02.012"},{"key":"2016101909071924000_38.3.e368.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.12.002"},{"key":"2016101909071924000_38.3.e368.19","doi-asserted-by":"publisher","DOI":"10.1159\/000279766"},{"key":"2016101909071924000_38.3.e368.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.01.003"},{"key":"2016101909071924000_38.3.e368.21","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2013020"},{"key":"2016101909071924000_38.3.e368.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.02.003"},{"key":"2016101909071924000_38.3.e368.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02843.x"},{"key":"2016101909071924000_38.3.e368.24","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12163"},{"key":"2016101909071924000_38.3.e368.25","doi-asserted-by":"publisher","DOI":"10.1037\/a0016302"},{"key":"2016101909071924000_38.3.e368.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.04.008"},{"key":"2016101909071924000_38.3.e368.27","doi-asserted-by":"publisher","DOI":"10.1159\/000320576"},{"key":"2016101909071924000_38.3.e368.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2012.00335.x"},{"key":"2016101909071924000_38.3.e368.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03014.x"},{"key":"2016101909071924000_38.3.e368.30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5055\/jom.2009.0032","article-title":"A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination","volume":"5","author":"Tacke","year":"2009","journal-title":"J Opioid Manage"},{"key":"2016101909071924000_38.3.e368.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.05.025"},{"key":"2016101909071924000_38.3.e368.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2014.07.009"},{"key":"2016101909071924000_38.3.e368.33","unstructured":"Lintzeris N , Clark N , Winstock A et al . National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Maintenance Treatment of Opioid Dependence, 2006. http:\/\/www.nationaldrugstrategy.gov.au\/internet\/drugstrategy\/publishing.nsf\/content\/9011C92D2F6E1FC5CA2575B4001353B6\/$File\/bupren.pdf (7 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.34","unstructured":"Department of Health (England) and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management . London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive."},{"key":"2016101909071924000_38.3.e368.35","unstructured":"Gowing L , Ali R , Dunlop A et al . National Guidelines for Medication-Assisted Treatment of Opioid Dependence National Guidelines for Medication-Assisted Treatment of Opioid Dependence, 2014. http:\/\/www.nationaldrugstrategy.gov.au\/internet\/drugstrategy\/Publishing.nsf\/content\/AD14DA97D8EE00E8CA257CD1001E0E5D\/$File\/National_Guidelines_2014.pdf (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.36","unstructured":"Hanford C et al . Buprenorphine\/naloxone for opioid dependence: clinical practice guideline . Toronto (ON): Centre for Addiction and Mental Health (CAMH), 2011. http:\/\/www.guideline.gov\/content.aspx?id=39351 (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.37","unstructured":"The College of Physicians & Surgeons of Ontario. Methadone Maintenance Treatment: Program Standards and Clinical Guidelines, 2011. https:\/\/www.cpso.on.ca\/uploadedFiles\/members\/MMT-Guidelines.pdf (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.38","unstructured":"Ministry of Health. 2008. Practice Guidelines for Opioid Substitution Treatment in New Zealand 2008 . Wellington: Ministry of Health. Published December 2008 Ministry of Health PO Box 5013, Wellington, New Zealand ISBN 978-0-478-31857-9 (print)."},{"key":"2016101909071924000_38.3.e368.39","unstructured":"Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. http:\/\/store.samhsa.gov\/shin\/content\/\/PEP15-FEDGUIDEOTP\/PEP15-FEDGUIDEOTP.pdf (12 October 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.40","unstructured":"United Nations International Narcotics Control Board. International Narcotics Control Board Report 2006, 2007. https:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2006\/AR_06_English.pdf (6 February 2015, date last accessed)."},{"key":"2016101909071924000_38.3.e368.41","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. EMCDDA Country Overview: Finland, 2015. [Online]. http:\/\/www.emcdda.europa.eu\/publications\/country-overviews\/fi (28 May 2015, date last accessed)."}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/38\/3\/e368\/8518619\/fdv150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T12:02:45Z","timestamp":1599739365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-lookup\/doi\/10.1093\/pubmed\/fdv150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,27]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,10,19]]},"published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1093\/pubmed\/fdv150"],"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdv150","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"value":"1741-3842","type":"print"},{"value":"1741-3850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,27]]}}}